MWA
AYTU icon

Moser Wealth Advisors’s AYTU BioPharma AYTU Stock Holding History

Moser Wealth Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$22 Hold
10
– – ﹤0.01% 200
2025
Q1 		$12 Buy
+10
New +$15 ﹤0.01% 162

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Moser Wealth Advisors's AYTU Position: Q2 2025 in Review

Moser Wealth Advisors held its AYTU BioPharma (AYTU) position steady in Q2 2025 at 10 shares worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #200.

Moser Wealth Advisors first reported a position in AYTU in Q1 2025 and has held it in 2 quarters since. 32 funds tracked by Wall St. Rank hold AYTU as of Q2 2025.

  • Moser Wealth Advisors held 10 shares of AYTU BioPharma worth $22 as of Q2 2025.
  • Moser Wealth Advisors left its AYTU BioPharma share count unchanged in Q2 2025.
  • AYTU BioPharma made up ﹤0.01% of Moser Wealth Advisors's portfolio in Q2 2025, its #200 holding.
  • Moser Wealth Advisors first reported a position in AYTU BioPharma in Q1 2025 and has held it in 2 quarters since.
  • 32 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2025.

Based on Moser Wealth Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.